Clinical Evidence: Digestive Side Effects Compared
Wegovy Constipation vs Mounjaro: Understanding the Difference
When comparing Wegovy constipation rates to Mounjaro, clinical evidence reveals important differences in gastrointestinal tolerance. Wegovy (semaglutide) works as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors, potentially affecting digestive function differently. In STEP clinical trials, constipation occurred in approximately 24% of Wegovy patients, whilst Mounjaro's SURMOUNT trials reported constipation in roughly 19% of participants. Both treatments slow gastric emptying as part of their weight management mechanism, but the dual-receptor action of tirzepatide may offer different gastrointestinal tolerance patterns for some patients.
The severity and duration of Wegovy constipation versus Mounjaro typically differs between individuals, with most digestive side effects being mild to moderate and transient. Wegovy's dose escalation over 16 weeks (0.25mg to 2.4mg) allows gradual adaptation, whilst Mounjaro's 20-week titration (2.5mg to 15mg maximum) provides even more flexibility for managing side effects. EverydayMeds stocks both treatments, enabling our prescribers to recommend the most suitable option based on your individual tolerance profile and clinical needs.
UK Pricing Comparison: Wegovy vs Mounjaro Costs
Wegovy constipation concerns shouldn't prevent you from accessing effective weight management treatment, especially when cost-effective options are available. Our Wegovy pricing starts at £79.99 for the 0.25mg starter pen (using code FIRST40 for new customers), progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Mounjaro pricing follows a different structure, with 2.5mg starting pens at £89.99, escalating through 5mg, 7.5mg, 10mg, 12.5mg, to 15mg maximum doses. Both treatments require prescription-only medicine protocols through our GPhC #9012878 registered pharmacy.
Bundle options provide convenient supply continuity for both treatments, with our Intro Duo (0.25mg & 0.5mg Wegovy) at £169.99 and Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 proving popular choices. Returning customers benefit from code DOSE25 at checkout, whilst our express prescriber review service (24-hour turnaround) ensures rapid access when switching between treatments due to Wegovy constipation or other tolerance issues.
Clinical Evidence: STEP vs SURMOUNT Trial Safety Data
Wegovy constipation data from the landmark STEP trials provides crucial safety insights for UK patients. In STEP 1, involving 1,961 participants, gastrointestinal side effects including constipation were the most commonly reported adverse events, typically occurring during dose escalation phases. The study, published by Wilding et al. in NEJM 2021, demonstrated that most digestive side effects were mild to moderate in severity and decreased over time as patients adapted to treatment.
Mounjaro's SURMOUNT trials similarly documented digestive side effects, with constipation rates varying across different doses and study populations. Both treatments carry MHRA Black Triangle ▼ status, indicating additional monitoring for safety data collection in real-world UK clinical practice. EverydayMeds' clinical team actively monitors patient responses to both treatments, providing ongoing support for side effect management.
How GLP-1 Treatments Affect Digestive Function
Understanding why Wegovy constipation occurs helps patients manage this common side effect more effectively. Semaglutide works by mimicking GLP-1, a natural incretin hormone that regulates blood glucose and gastric emptying, slowing food movement through the digestive system to promote satiety. This mechanism reduces appetite and increases feelings of fullness after smaller meals, but can also lead to constipation as food transit time increases. Mounjaro's dual GLP-1/GIP receptor action provides similar appetite suppression but may affect gastrointestinal motility differently due to its additional GIP pathway activation. Both treatments must be used alongside a reduced-calorie diet and increased physical activity, with adequate hydration and dietary fibre helping to minimise constipation risk.
EverydayMeds Ordering Process: Expert Clinical Support
Accessing both Wegovy and Mounjaro through EverydayMeds involves a comprehensive 3-minute online clinical assessment covering medical history, current medications, and side effect concerns including previous digestive issues. Our MHRA-approved prescribers review each application within 3 working days (or 24 hours with express service), specifically evaluating suitability for either treatment based on individual risk factors. Once approved, both treatments are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit. Our clinical team remains available for ongoing consultation about Wegovy constipation management or treatment switching if side effects become problematic. This comprehensive service ensures optimal treatment outcomes whilst maintaining the highest safety standards for both prescription-only medicines.
Storage and Practical Considerations: Wegovy vs Mounjaro
Wegovy constipation management extends to practical storage considerations that may influence treatment choice for some patients. Wegovy FlexTouch pens maintain stability for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, offering superior travel convenience compared to Mounjaro's 21-day room temperature limit. Both treatments require refrigerated storage at 2-8°C before first use, with similar once-weekly injection schedules using pre-filled pens. Wegovy's dose escalation follows a structured 16-week protocol (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg), whilst Mounjaro provides six dose strengths over 20 weeks, potentially allowing more gradual adaptation for patients prone to digestive side effects. The longer room temperature stability of Wegovy may benefit patients with active lifestyles or frequent travel requirements.
Managing Digestive Side Effects: Treatment Strategies
Effective Wegovy constipation management involves evidence-based strategies that our clinical team regularly discusses with patients. Gradual dose escalation remains crucial for both treatments, never skipping doses or accelerating titration schedules despite mild side effects. Dietary modifications including increased soluble fibre intake, adequate hydration (8-10 glasses daily), and regular physical activity can significantly improve digestive tolerance. Some patients find that timing injections consistently and maintaining regular meal schedules helps minimise gastrointestinal disruption with both Wegovy and Mounjaro.
When Wegovy constipation becomes problematic, switching to Mounjaro may offer improved tolerance due to its different receptor mechanism, though individual responses vary considerably. Our prescribers can facilitate treatment transitions based on side effect profiles and clinical response, ensuring continuous weight management support throughout the process. Both treatments may require lifestyle adjustments during the initial weeks, with most digestive side effects improving as the body adapts to treatment.
Expert Clinical Guidance: Choosing Between Treatments
EverydayMeds represents the UK's leading online pharmacy for comprehensive GLP-1 treatment comparison and supply, with both Wegovy and Mounjaro available through our GPhC #9012878 registered service. Our discount codes FIRST40 (new customers) and DOSE25 (returning customers) are applied at checkout to ensure competitive pricing for both treatments. Clinical consultations remain available throughout treatment for side effect management, dose adjustments, or treatment switching based on individual tolerance patterns. Whether you're experiencing Wegovy constipation or considering alternative options, our expert team provides personalised guidance to optimise your weight management outcomes. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and access both treatments through our secure, regulated service.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
